drugset / Trial / NCT07083011

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

NCT07083011

Phase 2 Recruiting 35 enrolled Mayo Clinic
Non-randomizedParallel-groupSingle-blindDiagnostic

Summary

The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)

Timeline

Start
2025-11-01
Primary completion
2027-07
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject FAPI GA-68 Diagnostic / imaging agent